Response to warfarin and other oral anticoagulants: Effects of disease states

Southern Medical Journal

Volumn 93, Issue 5, 2000, Pages 448-454

  Demirkan, Kutay ^b   Stephens, Mark A ^b   Newman, Kevin P ^b   Self, Timothy H ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

WARFARIN;

ANTICOAGULATION; ARTICLE; CONGESTIVE HEART FAILURE; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; FOOD DRUG INTERACTION; HUMAN; LIVER DISEASE; PROTEIN BINDING; THYROID DISEASE;

EID: 0034046004     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007611-200093050-00001     Document Type: Article

References (53)

1. Wells PS, Holbrook AN, Crowther NR, et al: Interactions of warfarin with drugs and food. Ann Intern Med 1994; 121:676-683
2. Hirsh J, Dalen JE, Anderson DR, et al: Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1998; 114(suppl):445s-469s
3. Donaldson GWK, Kavies SH, Darg A, et al: Coagulation factors in chronic liver disease. J Clin Pathol 1969; 22:199-204
4. Gallus AS, Lucas GR, Hirsh J: Coagulation studies in patients with acute infectious hepatitis. Br J Haematol 1972; 22:761-771
5. Koller F: Theory and experience behind the use of coagulation tests in diagnosis and prognosis of liver disease. Scand J Gastroenterol 1973; 8(suppl 19):51-61
6. Kovacs MJ, Wong A, MacKinnon K, et al: Assessment of the validity of the INR system for patients with liver impairment. Thromb Haemost 1994; 71:727-730
7. Mammen EF: Coagulation abnormalities in liver disease. Hematol Oncol Clin North Am 1992; 6:1247-1257
8. Reisner EH, Norman J, Field W, et al: The effect of liver dysfunction on the response to dicumarol. Am J Med Sci 1949; 217:445-447
9. Kliesch WF, Young PC, Davis WD, et al: Dangers of prolonged anticoagulant therapy in hepatic disease. JAMA 1960; 172:223-226
10. Williams RL, Schary WL, Blaschke TF, et al: Influence of acute viral hepatitis on disposition and pharmacologic effect of warfarin. Clin Pharmacol Ther 1976; 20:90-97
11. Landefeld CS, Cook EF, Flatley M, et al: Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy. Am J Med 1987; 82:703-713
12. Brigden ML, Kay C, Le A, et al: Audit of the frequency and clinical response to excessive oral anticoagulation in an out-patient population. Am J Hematol 1998; 59:22-27
13. Shenfield GM: Influence of thyroid dysfunction on drug pharmacokinetics. Clin Pharmacokinet 1981; 6:275-297
14. Owens JC, Neely WB, Owen WR: Effect of sodium dextrothyroxine in patients receiving anticoagulants. N Engl J Med 1962; 266:76-79
15. McIntosh TJ, Brunk SF, Kölln I, et al: Increased sensitivity to warfarin in thyrotoxicosis. J Clin Invest 1970; 49:63a
16. Vagenakis AG, Cote R, Miller ME, et al: Enhancement of warfarin-induced hypoprothrombinemia by thyrotoxicosis. Hopkins Med J 1972; 131:69-73
17. Self TH, Weisburst M, Wooten E, et al: Warfarin-induced hypoprothrombinemia; potentiation by hyperthyroidism. JAMA 1975; 231:1165-1166
18. Solomon HM, Schrogie JJ: Change in receptor site affinity: a proposed explanation for the potentiating effect of D-thyroxine on the anticoagulant response to warfarin. Clin Pharmacol Ther 1967; 8:797-799
19. Weintraub M, Breckinridge RT, Griner PF, et al: The effects of dextrothyroxine on the kinetics of prothrombin activity: proposed mechanism of the potentiation of warfarin by D-thyroxin. J Lab Clin Med 1973; 81:273-279
20. Loeliger EA, van der Esch B, Mattern MJ, et al: The biological disappearance rate of prothrombin, factors VII, IX, and X from plasma in hypothyroidism, hyperthyroidism, and during fever. Thromb Diath Haemorrh 1964; 10:267-277
21. Kellett HA, Sawers JSA, Boulton FE, et al: Problems of anticoagulation with warfarin in hyperthyroidism. Q J Med 1986; 58:43-51
22. Walters MB: The relationship between thyroid function and anticoagulation therapy. Am J Cardiol 1963; 11:112-114
23. Stephens MA, Self TH, Lancaster D, et al: Hypothyroidism: effect on warfarin anticoagulation. South Med J 1989; 82:1585-1586
24. Stats D, Davison S: The increased hypoprothrombinemic effect of a small dose of dicoumarol in congestive heart failure. Am J Med Sci 1949; 218:318-323
25. Killip T, Payne MA: High serum transaminase activity in heart disease. Circulation 1960; 21:646-660
26. O'Reilly RA, Sahud MA, Aggeler PM: Impact of aspirin and chlorthalidone on the pharmaco-dynamics of oral anticoagulant drugs on man. Ann NY Acad Sci 1971; 179:173-186
27. O'Reilly RA: Interaction of spironolactone and racemic warfarin in man. Clin Pharmacol Ther 1980; 27:198-201
28. Peyman MA: The significance of hemorrhage during the treatment of patients with coumarin anticoagulants. Acta Med Scand 1958; 162(suppl):1-62
29. Oates A, Jackson PR, Austin CA, et al: A new regimen for starting warfarin therapy in out-patients. Br J Clin Pharmacol 1998; 46:157-161
30. Petitti DB, Storm BL, Melmon KL: Prothrombin time ratio and other factors associated with bleeding in patients treated with warfarin. J Clin Epidemiol 1989; 42:759-764
31. Doecke CJ, Cosh DG, Gallus AS: Standardized initial warfarin treatment: evaluation of initial treatment response and maintenance dose prediction by randomized trial, and risk factors for an excessive warfarin response. Aust NZ J Med 1991; 21:319-324
32. O'Reilly RA, Aggeler PA: Determinants of the response to oral anticoagulant drugs in man. Pharmacol Rev 1970; 22:35-96
33. Coumadin (warfarin) package insert. Wilmington, Del, DuPont Pharma, 1998
34. Ifudu O, Dulin A: Pharmacokinetics and dialysability of warfarin in endstage renal disease. Nephron 1993; 65:150-151
35. Bachmann K, Shapiro R, Mackiewicz J: Influence of renal dysfunction on warfarin plasma protein binding. J Clin Pharmacol 1976; 16:468-472
36. Bachmann K, Shapiro R, Mackiewicz J: Warfarin elimination and responsiveness in patients with renal dysfunction. J Clin Pharmacol 1977; 17:292-299
37. Sachs JJ, Henderson R: Use of bishydroxycoumarin (dicumarol) in the presence of impaired renal function. JAMA 1952; 148:839-841
38. Landefeld CS, Goldman L: Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989; 87:144-152
39. Bona RD, Sivjee KY, Hickey AD, et al: The efficacy and safely of oral anticoagulation in patients with cancer. Thromb Haemost 1995; 74:1055-1058
40. Richards RK: Influence of fever upon the action of 3,3′-methylene-bis-(4-hydroxy-coumarin) (dicumarol). Science 1943; 97:313
41. Powell JR, Vozeh S, Hopewell P, et al: Theophylline disposition in acutely ill hospitalized patients: the effect smoking, heart failure, severe airway obstruction and pneumonia. Am Rev Respir Dis 1978; 118:229-238
42. Chang KC, Lauer BA, Bell TD, et al: Altered theophylline pharmacokinetics during acute respiratory viral illness. Lancet 1978; 1:1132-1133
43. Sonne J, Dossing M, Loft S, et al: Antipyrine clearance in pneumonia. Clin Pharmacol Ther 1985; 37:701-704
44. Sharer JE, Wrighton SA: Identification of the human hepatic cytochromes P450 involved in the in vitro oxidation of antipyrine. Drug Metab Dispos 1996; 24:487-494
45. Miners JO, Birkett DJ: Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998; 45:525-538
46. Kroemer HK, Fromm MF, Eichelbaum M: Stereoselectivity in drug metabolism and action: effects of enzyme inhibition and induction. Ther Drug Monit 1996; 18:388-392
47. Shedlofsky SI, Israel BC, McClain CJ, et al: Endotoxin administration to humans inhibits hepatic cytochrome P450-mediated drug metabolism. J Clin Invest 1994; 94:2209-2114
48. Oester YT, Keresztes-Nagy S, Mais RF, et al: Effect of temperature on binding of warfarin by human serum albumin. J Pharm Sci 1976; 65:1673-1677
49. Black JA: Diarrhoea, vitamin K, and warfarin. Lancet 1994; 344:1373
50. Narasimhan P: Decreased sensitivity to oral anticoagulant therapy after attacks of migraine. Lancet 1974; 2:1143
51. Nicholls DP, Shepherd AM: Altered warfarin metabolism in iron-deficient patient. Lancet 1978; 2:215-216
52. Khamashta MA, Cuadrado MJ, Mujic F, et al: The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332:993-997
53. Aithal GP, Day CP, Kesteven PJL, et al: Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353:717-719